carmofur has been researched along with Carcinoma, Transitional Cell in 1 studies
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 5.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| "To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out." | 1.28 | [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wada, S | 1 |
| Yasumoto, R | 1 |
| Kashihara, N | 1 |
| Kishimoto, T | 1 |
| Maekawa, M | 1 |
| Hayahara, N | 1 |
| Kawakita, J | 1 |
| Nishijima, T | 1 |
| Morikawa, Y | 1 |
| Horii, A | 1 |
1 other study available for carmofur and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 1992 |